With the USP <382> deadline still fast approaching on December 1, 2025, our recent webinar made one thing clear: teams are taking action.
The urgency of this transition is not to be taken lightly, and now is the time to take a closer look at your drug packaging and integrity testing strategies to stay ahead of regulatory & compliance changes to avoid last-minute challenges.
FAQs About 12/1/2025 Deadline:
How exactly does USP <382> differ from <381>?
USP <382> replaces USP <381> by expanding the scope of testing from the elastomer component alone to the complete container closure system, emphasizing functional suitability under real-world conditions for integrated drug delivery systems.
How does Annex 1 connect to Container Closure Integrity Testing (CCIT)?
Annex 1 reinforces sterility assurance by requiring validated, deterministic CCIT methods, such as vacuum decay or high-voltage leak detection, to demonstrate closure integrity. Visual inspection, while still mandatory for defect detection, can no longer be used as proof of system integrity.
Request Access: https://info.gatewayanalytical.com/converging-standards-for-sterile-packaging-compliance
Key Revelations:
System-level assessment is mandatory.
Visual inspection is no longer sufficient.
Deterministic methods drive compliance.
While the December 2025 deadline approaches, trust the experts at Gateway Analytical to guide your compliance strategy. Our team bridges regulatory and technical gaps through system-level analytical testing, USP <382> functional suitability assessments, and deterministic CCIT programs. These services ensure packaging integrity, regulatory alignment, and launch readiness as the industry transitions into a new era of pharmaceutical packaging.
